person · Reporting owner

MINOGUE MICHAEL R

Disclosed activity across 2 companies

Tapewire entity: 45352
SEC CIK: 0001286370

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSULET CORPPODD · Entity 3516	Director	May 20, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSULET CORP

Report date May 20, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,438	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 2,438 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
Common StockSEC Table I · non-derivative	IndirectBy Trust	17,483	Reported balance Holding disclosure · report date 2026-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 17,483

Filing footnotes · ownership attribution and instrument terms

F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABIOMED INC

Report date December 22, 2022 · Filed December 27, 2022

Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock $.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-12-22 transaction · row 1 1 source row Row 1 · 2022-12-22 · Disposition to issuer · Disposed 166,670 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
Common Stock $.01 par valueSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2022-12-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-12-22 · Disposition to issuer · Disposed 243,962 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.55 · Expires 2024-05-14	Direct	0	Reported balance After 2022-12-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-12-22 · Disposition to issuer · Disposed 85,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.25 · Expires 2025-05-13	Direct	0	Reported balance After 2022-12-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-12-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2026-05-24	Direct	0	Reported balance After 2022-12-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-12-22 · Disposition to issuer · Disposed 30,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15	Direct	0	Reported balance After 2022-12-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-12-22 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.97 · Expires 2028-05-16	Direct	0	Reported balance After 2022-12-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30	Direct	0	Reported balance After 2022-12-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-12-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29	Direct	0	Reported balance After 2022-12-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-12-22 · Disposition to issuer · Disposed 20,898 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25	Direct	0	Reported balance After 2022-12-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	96,265	Reported balance After 2022-12-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-12-22 · Grant · Acquired 96,265 · Balance 96,265 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-12-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-12-22 · Disposition to issuer · Disposed 96,265 · Balance 0 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.

F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.

F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.

F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option;

F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.

F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)

F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 27, 2019 Filed Jan 6, 2020 22:10 UTC	INSULET CORP PODD · Entity 3516	GiftCommon Stock	4,564	$0.00	$0.00	Disclosure SEC source: 0001127602-20-001187 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,564 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document
November 27, 2019 Filed Jan 6, 2020 22:10 UTC	INSULET CORP PODD · Entity 3516	GiftCommon Stock	4,564	$0.00	$0.00	Disclosure SEC source: 0001127602-20-001187 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:25 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	8	$0.00	$0.00	Disclosure SEC source: 0001179110-19-010751 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,716 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document
June 15, 2019 Filed Jun 19, 2019 17:30 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	51,332	$250.96	$12,882,278.72	Disclosure SEC source: 0001179110-19-007885 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,708 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 30, 2019 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $266.39	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · derivative · entry 20 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-05-30 F4 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document
May 30, 2019 Filed Jun 3, 2019 21:45 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,726	$0.00	$0.00	Disclosure SEC source: 0001127602-19-020541 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,084 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis. Read SEC document
May 29, 2019 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	29,850	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 31,672 F5 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F5 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. Read SEC document
May 29, 2019 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	29,850	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,040 F5 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F5 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. Read SEC document
May 24, 2019 Filed May 29, 2019 16:40 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	7,193	$262.64	$1,889,169.52	Disclosure SEC source: 0001179110-19-006789 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,908 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 16, 2019 Filed May 17, 2019 16:18 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	4,546	$259.68	$1,180,505.28	Disclosure SEC source: 0001179110-19-006272 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,101 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 16, 2019 Filed May 17, 2019 16:18 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	1,632	$259.68	$423,797.76	Disclosure SEC source: 0001179110-19-006272 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,647 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 16, 2019 Filed May 17, 2019 16:18 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	30,646	$0.00	$0.00	Disclosure SEC source: 0001179110-19-006272 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,279 F6 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 16, 2018. One third of these restricted stock units vested on May 16, 2019 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F6 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 16, 2018. One third of these restricted stock units vested on May 16, 2019 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
May 15, 2019 Filed May 17, 2019 16:18 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	2,062	$256.69	$529,294.78	Disclosure SEC source: 0001179110-19-006272 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,633 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 15, 2019 Filed May 17, 2019 16:18 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	8,506	$256.69	$2,183,405.14	Disclosure SEC source: 0001179110-19-006272 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,695 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
March 31, 2019 Filed Apr 2, 2019 17:11 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	51	$0.00	$0.00	Disclosure SEC source: 0001179110-19-004532 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,201 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document
November 21, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	85,040	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 12 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - F Disclosed balance after: 85,040 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust Read SEC document
November 21, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	85,040	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 1,822 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust Read SEC document
November 20, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	23,810	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - C Disclosed balance after: 32,810 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for a foundation account F6 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for a foundation account Read SEC document
November 20, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	23,810	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 86,862 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for a foundation account F6 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for a foundation account Read SEC document
August 09, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	64,018	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 110,672 F5 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F5 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. Read SEC document
August 09, 2018 Filed Jun 3, 2019 16:47 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	64,018	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007007 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,890 F5 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F5 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionStock Option (right to buy) · Derivative	105,000	$0.00 Strike: $10.03	$0.00	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · derivative · entry 21 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2020-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Exercise of stock options pursuant to reporting owner's 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owner's 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,000	$450.06	$450,060.00	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 15 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,150 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	4,165	$447.01	$1,861,779.57	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 14 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,150 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F19 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $446.8300 and $447.2800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,605	$445.92	$715,707.54	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 13 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,315 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F18 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $445.6700 and $446.5000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	4,325	$445.17	$1,925,352.03	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 12 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,920 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F17 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $444.5400 and $445.5100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	3,300	$443.77	$1,464,448.92	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 11 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,245 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F16 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $443.4300 and $444.0700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	1,293	$442.75	$572,472.78	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 10 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,545 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F15 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $442.3700 and $442.9000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	3,634	$441.75	$1,605,323.86	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,838 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F14 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $441.1800 and $442.1500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	6,696	$440.60	$2,950,283.04	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 8 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,472 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F13 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $440.1700 and $441.0800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	24,497	$439.74	$10,772,278.93	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 7 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,168 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F12 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $439.1700 and $440.1600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	30,611	$438.65	$13,427,539.64	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,655 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F11 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $438.1700 and $439.1400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	8,009	$437.88	$3,507,012.96	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,276 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F10 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $437.1900 and $438.1600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	5,481	$436.76	$2,393,877.18	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,285 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F9 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $436.1800 and $437.1700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	7,984	$435.63	$3,478,097.07	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,766 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $435.1400 and $436.0400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock $.01 par value	2,400	$434.47	$1,042,737.12	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,750 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $434.0900 and $435.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
June 21, 2018 Filed Jun 25, 2018 17:03 UTC	ABIOMED INC ABMD · Entity 121309	Exercise / conversionCommon Stock $.01 par value	105,000	$10.03	$1,053,150.00	Disclosure SEC source: 0001179110-18-009007 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owner's 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owner's 10b5-1 plan. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:36 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	9,240	$440.65	$4,071,606.00	Disclosure SEC source: 0001179110-18-008796 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,150 F7 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F7 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:36 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	42,092	$440.65	$18,547,839.80	Disclosure SEC source: 0001179110-18-008796 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,390 F7 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F7 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:36 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	41,526	$0.00	$0.00	Disclosure SEC source: 0001179110-18-008796 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,482 F6 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 14, 2016. One half of these restricted stock units vested on June 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on June 15, 2019 as long as the reporting person continues to be employed by the issuer on the vesting dates F6 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 14, 2016. One half of these restricted stock units vested on June 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on June 15, 2019 as long as the reporting person continues to be employed by the issuer on the vesting dates Read SEC document
June 15, 2018 Filed Jun 19, 2018 17:36 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	189,174	$0.00	$0.00	Disclosure SEC source: 0001179110-18-008796 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,956 F5 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on June 15, 2015. One half of these restricted stock units vested on June 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on June 15, 2019 as long as the reporting person continues to be employed by the issuer on the vesting dates. F5 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on June 15, 2015. One half of these restricted stock units vested on June 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on June 15, 2019 as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
May 24, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock $.01 par value	7,192	$395.52	$2,844,579.84	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,962 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	38,560	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - E Disclosed balance after: 38,560 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	35,745	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - B Disclosed balance after: 73,745 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	38,560	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 46,654 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	35,745	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 85,214 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	1,180	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 120,959 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 18, 2018 Filed May 25, 2018 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GiftCommon Stock $.01 par value	1,180	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007551 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,782 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
May 16, 2018 Filed May 18, 2018 18:00 UTC	ABIOMED INC ABMD · Entity 121309	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $381.97	$0.00	Disclosure SEC source: 0001179110-18-007130 · edgar.xml · derivative · entry 13 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-16 F4 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document
May 16, 2018 Filed May 18, 2018 18:00 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock $.01 par value	11,000	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007130 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,154 F5 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 16, 2019, May 16, 2020 and May 16, 2021, so long as the reporting person continues to be employed by the issuer on the vesting dates. F5 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 16, 2019, May 16, 2020 and May 16, 2021, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.